{"downloaded": true, "htmlmade": false, "full": {"id": "29984830", "source": "MED", "pmid": "29984830", "pmcid": "PMC6175065", "fullTextIdList": {"fullTextId": "PMC6175065"}, "doi": "10.1111/bjh.15459", "title": "Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.", "authorString": "Royle KL, Gregory WM, Cairns DA, Bell SE, Cook G, Owen RG, Drayson MT, Davies FE, Jackson GH, Morgan GJ, Child JA.", "authorList": {"author": [{"fullName": "Royle KL", "firstName": "Kara-Louise", "lastName": "Royle", "initials": "KL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CTRU, University of Leeds, Leeds, UK."}}}, {"fullName": "Gregory WM", "firstName": "Walter M", "lastName": "Gregory", "initials": "WM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CTRU, University of Leeds, Leeds, UK."}}}, {"fullName": "Cairns DA", "firstName": "David A", "lastName": "Cairns", "initials": "DA", "authorId": {"@type": "ORCID", "#text": "0000-0002-2338-0179"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CTRU, University of Leeds, Leeds, UK."}}}, {"fullName": "Bell SE", "firstName": "Sue E", "lastName": "Bell", "initials": "SE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CTRU, University of Leeds, Leeds, UK."}}}, {"fullName": "Cook G", "firstName": "Gordon", "lastName": "Cook", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "LICAP, University of Leeds, Leeds, UK."}}}, {"fullName": "Owen RG", "firstName": "Roger G", "lastName": "Owen", "initials": "RG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "HMDS, St James's University Hospital, Leeds, UK."}}}, {"fullName": "Drayson MT", "firstName": "Mark T", "lastName": "Drayson", "initials": "MT", "authorId": {"@type": "ORCID", "#text": "0000-0002-1528-7564"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinical Immunology Service, University of Birmingham, Birmingham, UK."}}}, {"fullName": "Davies FE", "firstName": "Faith E", "lastName": "Davies", "initials": "FE", "authorId": {"@type": "ORCID", "#text": "0000-0002-3971-2393"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Institute of Cancer Research, Sutton, UK."}}}, {"fullName": "Jackson GH", "firstName": "Graham H", "lastName": "Jackson", "initials": "GH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Northern Cancer Centre, Newcastle University, Newcastle-upon-Tyne, UK."}}}, {"fullName": "Morgan GJ", "firstName": "Gareth J", "lastName": "Morgan", "initials": "GJ", "authorId": {"@type": "ORCID", "#text": "0000-0002-4271-6360"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Institute of Cancer Research, Sutton, UK."}}}, {"fullName": "Child JA", "firstName": "J Anthony", "lastName": "Child", "initials": "JA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CTRU, University of Leeds, Leeds, UK."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-1528-7564"}, {"@type": "ORCID", "#text": "0000-0002-2338-0179"}, {"@type": "ORCID", "#text": "0000-0002-3971-2393"}, {"@type": "ORCID", "#text": "0000-0002-4271-6360"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "6", "volume": "182", "journalIssueId": "2724452", "dateOfPublication": "2018 Sep", "monthOfPublication": "9", "yearOfPublication": "2018", "printPublicationDate": "2018-09-01", "journal": {"title": "British journal of haematology", "ISOAbbreviation": "Br J Haematol", "medlineAbbreviation": "Br J Haematol", "NLMid": "0372544", "ISSN": "0007-1048", "ESSN": "1365-2141"}}, "pubYear": "2018", "pageInfo": "816-829", "abstractText": "In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) or cyclophosphamide, thalidomide and dexamethasone (CTD) followed by autologous stem cell transplant (ASCT) in the intensive pathway; attenuated CTD or melphalan and prednisolone (MP) in the non-intensive pathway. Subsequent randomisation allocated patients to either thalidomide or observation. The European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaires, QLQ-C30 and QLQ-MY24, were administered at baseline, 3, 6 and 12\u00a0months and annually thereafter, enabling the effect of sequential treatment on patient-reported health-related QoL (HR-QoL) to be investigated. The protocol specified four subscales of interest: Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6 and 12\u00a0months that were compared using linear models. The intensive pathway showed significant differences in favour of CTD for Fatigue at 3\u00a0months and Physical Functioning at 12\u00a0months. The non-intensive pathway and maintenance phase reported significant differences at 3\u00a0months; Pain (improved with attenuated CTD) and Global Health status/Quality of Life (improved with observation). The improved outcomes in MRC Myeloma IX were accompanied by some beneficial and few detrimental effects on HR-QoL.", "affiliation": "CTRU, University of Leeds, Leeds, UK.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Randomized Controlled Trial", "Journal Article"]}, "grantsList": {"grant": {"grantId": "G0100132", "agency": "Medical Research Council", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "PX", "qualifierName": "psychology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Thalidomide", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Clodronic Acid", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Remission Induction", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Transplantation", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Transplantation, Autologous"}, {"majorTopic_YN": "N", "descriptorName": "Longitudinal Studies"}, {"majorTopic_YN": "Y", "descriptorName": "Quality of Life"}, {"majorTopic_YN": "N", "descriptorName": "Adolescent"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}, {"majorTopic_YN": "N", "descriptorName": "Self Report"}, {"majorTopic_YN": "N", "descriptorName": "Consolidation Chemotherapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Maintenance Chemotherapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Surveys and Questionnaires"}, {"majorTopic_YN": "N", "descriptorName": "Zoledronic Acid", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}]}, "keywordList": {"keyword": ["Multiple myeloma", "Quality of life", "Immunomodulatory Agent", "Eortc Qlq-c30", "Eortc My-24"]}, "chemicalList": {"chemical": [{"name": "Thalidomide", "registryNumber": "4Z8R6ORS6L"}, {"name": "Clodronic Acid", "registryNumber": "0813BZ6866"}, {"name": "zoledronic acid", "registryNumber": "6XC1PAD3KF"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15459"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6175065"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6175065?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "5", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-07-16", "dateOfCreation": "2018-07-10", "firstIndexDate": "2018-07-09", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2019-10-08", "electronicPublicationDate": "2018-07-09", "firstPublicationDate": "2018-07-09"}, "htmllinks": "https://europepmc.org/articles/PMC6175065", "abstract": "In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) or cyclophosphamide, thalidomide and dexamethasone (CTD) followed by autologous stem cell transplant (ASCT) in the intensive pathway; attenuated CTD or melphalan and prednisolone (MP) in the non-intensive pathway. Subsequent randomisation allocated patients to either thalidomide or observation. The European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaires, QLQ-C30 and QLQ-MY24, were administered at baseline, 3, 6 and 12\u00a0months and annually thereafter, enabling the effect of sequential treatment on patient-reported health-related QoL (HR-QoL) to be investigated. The protocol specified four subscales of interest: Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6 and 12\u00a0months that were compared using linear models. The intensive pathway showed significant differences in favour of CTD for Fatigue at 3\u00a0months and Physical Functioning at 12\u00a0months. The non-intensive pathway and maintenance phase reported significant differences at 3\u00a0months; Pain (improved with attenuated CTD) and Global Health status/Quality of Life (improved with observation). The improved outcomes in MRC Myeloma IX were accompanied by some beneficial and few detrimental effects on HR-QoL.", "Keywords": ["Multiple myeloma", "Quality of life", "Immunomodulatory Agent", "Eortc Qlq-c30", "Eortc My-24"], "pdflinks": "https://europepmc.org/articles/PMC6175065?pdf=render", "journaltitle": "British journal of haematology", "authorinfo": ["Royle KL", "Gregory WM", "Cairns DA", "Bell SE", "Cook G", "Owen RG", "Drayson MT", "Davies FE", "Jackson GH", "Morgan GJ", "Child JA"], "title": "Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study."}